Glenmark Pharmaceuticals’ subsidiary, Glenmark USA, has reached a settlement to resolve long-standing antitrust and consumer protection lawsuits in the United States. The company has agreed to a total payment of $29.628 million to be disbursed in annual installments over five years. This settlement, which requires court approval, does not constitute an admission of liability or wrongdoing, and the financial impact has already been provided for in the company’s current financials.
Resolution of Legal Proceedings
Glenmark Pharmaceuticals Ltd. announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, has finalized a settlement agreement regarding multiple antitrust and consumer protection lawsuits. These proceedings, which have been active since 2016, involved allegations of anti-competitive conduct, price-fixing, and market allocation concerning generic pharmaceutical products.
Settlement Details and Financial Impact
Under the terms of the agreement, Glenmark USA will pay a total of $29.628 million to state attorneys general and other plaintiffs. The payment is structured as annual installments spanning five years. Crucially, the company maintains that this settlement is entered into to avoid the uncertainty and costs of ongoing litigation; it is not an admission of guilt, liability, or illegal activity.
Financial Outlook
The company confirmed that the full settlement amount has already been accounted for within its financial records. Management has stated that the resolution of these legal matters will not have a significant impact on the overall financial position of the company. The settlement remains subject to final approval by the court overseeing the litigation.
Source: BSE
